Abstract
Orthotopic heart transplantation (HTX) represents the gold standard treatment for patients with advanced heart failure. The post-transplant survival of adult HTX recipients has consistently improved in past decades. As a result of increasing donor-recipient mismatch, as well as important technical and surgical advances, the attention of the medical community has shifted to ventricular assist devices (VADs) and to total artificial hearts. Here we present a patient who survived for 29 years after HTX at the age of 34 – a Caucasian male who manifested exceptionally few of the usual major post-HTX complications and was without typical cardiac allograft vasculopathy on autopsy. The scientific and medical community should not hesitate to persist with vigorous efforts to support research in transplantation and promote organ donation among the general population.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
